Citations

Clear

1011 citation(s) found for "Barry, WT".

Impact of sglt2 inhibitors on cardiovascular outcomes in patients with acute myocardial infarction
Ibrahim, Risqot Garba , Mee, Xuan Ci , Pham, Huyen Q., Abdelnabi, Mahmoud , Bcharah, George , Barry, Timothy, Fariña, Juliana, Ayoub, Chadi , Lee, K, Lim, G, Pham, H, Salih, Mustafa Abdalla M , Farina, J, Arsanjani, Reza

Mayo Clinic

European Journal of Preventive Cardiology | May 19, 2025 | Volume: 32 | Issue: Supplement_1 | Pages: No page available

10.1093/eurjpc/zwaf236.239 Get It

Abstract Background Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) have emerged as a vital component in the management of heart failure (HF), demonstrating significant improvements in cardiac function. However, their impact on outcomes in patients with acute myocardial infarction (AMI) remains poorly characterized. This study aimed to evaluate the long-term outcomes of SGLT2-Is among patients with AMI. Methods We conducted a retrospective cohort study using data from the TriNetX Banner Health Network platform in the United States, including patients aged ≥18 years with AMI identified through ICD-10 codes. Patients were categorized into two cohorts based on SGLT2-I use. Propensity score matching (PSM) was performed to balance baseline demographics, comorbidities (e.g., hypertension, diabetes, chronic kidney disease, heart failure, and hyperlipidemia), and medication use (e.g., heart failure therapies, antiplatelet agents, anticoagulants). Risk ratios (RRs) and 95% confidence intervals (95% CIs) were estimated for the following cardiovascular outcomes: acute HF hospitalizations, stroke, all-cause hospitalizations, recurrent AMI, cardiac arrest, and new-onset atrial fibrillation (AF). Kaplan-Meier analysis was completed to estimate survival probability from all-cause hospitalizations. Results After PSM, 2,440 patients were analyzed (1,220 SGLT2-I users; 1,220 non-users). Both cohorts had similar characteristics without any residual imbalance: mean age 67.7 years in the SGLT2-I group vs. 67.5 years in non-users, and both groups included 85.2% White and 33.6% female patients. Mean follow-up duration was 608 days for SGLT2-I users and 1,013.5 days for non-users. SGLT2-I use was associated with significantly lower rates of all-cause hospitalizations (RR: 0.712; 95% CI: 0.652–0.777), HF-related hospitalizations (RR: 0.878; 95% CI: 0.781–0.987), recurrent AMI (RR: 0.821; 95% CI: 0.703–0.959), and cardiac arrest (RR: 0.500; 95% CI: 0.345–0.725). No significant differences were observed in stroke (RR: 0.909; 95% CI: 0.702–1.178) or new-onset AF (RR: 0.889; 95% CI: 0.782–1.010) between the cohorts. Conclusions SGLT2-Is are associated with improved cardiovascular outcomes in patients with AMI, including reductions in all-cause and HF-related hospitalizations, recurrent AMI, and cardiac arrest. While these findings are hypothesis-generating, they emphasize the need for prospective clinical trials to confirm these results.Kaplan-Meier Analysis.
Atrioventricular Dyssynchrony and Dyspnea in Heart Failure With Preserved Ejection Fraction
Donisan, Teodora , Inglis, Sara S. , Asirvatham, Samuel J. , Borlaug, Barry A. , Inglis, Sara S , Asirvatham, Samuel J , Borlaug, Barry A

Mayo Clinic

Circulation: Heart Failure | May 19, 2025 | Volume: 18 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.125.013183 | PMID 40384453 Get It

The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Quantitative in Vivo Microscopic Assessment and Computer Aided Diagnosis of Early Interstitial Lung Disease Using Artificial Intelligence Based Endobronchial Optical Coherence Tomography
Nandy, Sreyankar , Berigei, S.R., Garcia-Moliner, Maria, Raphaely, Rebecca A., Calmo, N., Lee, J., Zhao, Sophia , Wright, C , Auchincloss, Hugh, Washko, G.R., Keyes, Colleen , Smith, Maxwell L. , VanderLaan, Paul A. , Calmo, Nery Matias , Yamamoto, Shuji , Shea, Barry S. , Lanuti, Michael D. , Sachdeva, Uma M , Washko, G.R., Herrmann, Markus D. , Hariri, Lida P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A5353-A5353

10.1164/ajrccm.2025.211.abstracts.a5353 Get It

Abstract Introduction: Endobronchial optical coherence tomography (EB-OCT) imaging has unique potential to diagnose and quantify early, microscopic disease changes and assess therapeutic responsivity in interstitial lung disease (ILD). However, training and time requirements for interpretation and quantitative evaluation of large volumetric EB-OCT datasets need to be optimized to facilitate clinical adoption. We develop and validate a computationally-efficient, rapid EB-OCT quantitative image analysis framework using artificial intelligence (AI) with deep learning architecture for 2D feature segmentation, 3D feature burden and spatial distribution mapping, and computer-aided diagnosis in early ILD subjects. Methods: Volumetric EB-OCT datasets, consisting of 2D cross-sectional images, were acquired from multiple locations in the bilateral lungs of ILD and healthy control subjects. EB-OCT features were manually segmented from cross-sectional images by an expert EB-OCT reader, including fibrosis, microscopic honeycombing, traction bronchiolectasis, normal parenchyma, and emphysema. EB-OCT images with corresponding feature segmentations were used to train and validate a multiclass convolutional neural network. The 2D AI-based segmentation model was subsequently evaluated against manual ‘ground truth’ segmentations for each feature in a de novo ‘test’ dataset of independent subjects using dice similarity score, precision, recall/sensitivity, specificity, and balanced accuracy. To generate 3D AI-based quantitative feature burden and spatial distribution maps, AI-based feature segmentation was performed on each EB-OCT 2D cross-sectional image within a volumetric imaging site. Three external pathologist readers independently interpreted 3D AI-based features maps for each EB-OCT imaging site acquired for a subject (without access to EB-OCT images) and provided a single diagnosis of usual interstitial pneumonia (UIP) or non-UIP ILD. Performance of computer-aided ILD diagnosis was compared against independently evaluated histopathology, clinical diagnosis, and prior EB-OCT image interpretation. Results: EB-OCT was acquired in 51 subjects: 30 in vivo early ILD, 5 in vivo non-ILD controls, and 16 ex vivo end-stage ILD. Overall pixel similarity between 2D manual and AI-based segmentation demonstrated high accuracy for each ILD feature (mean balanced accuracy 0.9). 3D quantitative AI-based feature maps demonstrated strong agreement (Spearman ρ0.87, p<0.001) between manual and AI-based segmentation. AI-based computer-aided diagnosis demonstrated 100% sensitivity/specificity for histologic UIP and clinical IPF for all pathologist readers, with improved diagnostic accuracy and significantly reduced training (45-minute training, 75% reduction) and interpretation time (<1 minute per subject for computer-aided diagnosis, 88% reduction) compared to EB-OCT image interpretation. Conclusion: The AI-based EB-OCT image analysis framework could expedite computer-aided diagnosis of early ILD and robust, quantitative assessment of microscopic disease burden, progression, and therapeutic responsivity.
Assessing the Utility of Provocative Maneuvers During Right Heart Catheterization in Pulmonary Venous Hypertension
Mendoza, Marco Patricio Bravo, Reddy, Yogesh N.V. , Hassoun, P.M., Hill, Nicholas S. , Erzurum, Serpil C. , Beck, Gerald J. , Finet, Emanuel, Jellis, C.L., Mathai, Stephen C. , Nishimura, Rick , Mathai, Stephen C , Frantz, Robert P. , Hassoun, P.M., Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rosenzweig, Erika B. , Mehra, Reena , Borlaug, Barry A. , Rischard, Franz

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 11, 2025 | Volume: 211 | Issue: Supplement_1 | Pages: A3283-A3283

10.1164/ajrccm.2025.211.abstracts.a3283 Get It

Abstract Rationale: Although guidelines recommend the use of provocative testing to diagnose pulmonary venous hypertension (PVH) that is unapparent at normal resting right heart catheterization (RHC), the incremental value of provocative testing is unknown. We aim to evaluate the incremental diagnostic capability of inhaled nitric oxide (iNO), fluid challenge (FC) or invasive cardiopulmonary exercise testing (iCPET) to unmask PVH using previously defined hemodynamic cutoffs. Methods: We included subjects from the NHLBI-funded Pulmonary Vascular Disease Phenomics (PVDOMICS) study. Our analysis included patients with World Symposium on Pulmonary Hypertension (WSPH) Group 2 disease (G2PH) and G2PH comparators (WSPH Group 2 phenotype without a diagnosis of PH) as determined by the PI or adjudication panel. We then applied a protocol-driven provocative approach based on the feasibility of modalities available in most catheterization labs. Using a pulmonary capillary wedge pressure (PCWP) cutoff of >15, frequencies were identified for subjects based on resting PCWP and with iNO. Frequencies were also identified for: those who received FC with a PCWP cutoff of ≥18 or those who received iCPET with PCWP cutoff of >20 (upright) or >25 (supine). Results: There were 419 subjects identified with WSPH Group 2 disease (Figure). Roughly half were found to have a PCWP >15 during resting RHC (N = 207). Of the remaining subjects with a resting PCWP ≤15 (N = 150), 42 subjects were found to have a PCWP >15 with iNO administration (40.0%). Of the remaining 63 subjects with PCWP ≤15 following iNO administration, nearly half (N = 26, 48.0%) demonstrated a PCWP ≥18 following FC while 8 subjects (14.8%) demonstrated an elevated PCWP following iCPET. Conclusions: There is a high proportion of G2PH patients (∼35%) who appear hemodynamically similar to precapillary PH at rest. Inhaled nitric oxide vasodilatory challenge unmasks G2PH in many patients. In situations where iNO does not disclose the G2PH phenotype, provocation with FC or iCPET can be useful as a supplementary provocative maneuver. Future directions will focus on agnostically assessing the utility of provocation based on grouping subjects by resting hemodynamics as well as assessing the use of provocation in other forms of PH.
An Intervention to Increase Advance Care Planning Among Older Adults With Advanced Cancer
Volandes, Angelo E., Chang, Yuchiao , Paasche‐Orlow, Michael K. , Lindvall, Charlotta , Zupanc, Seth N., Martins-Welch, Diana , Carney, Maria Torroella , Burns, Edith , Itty, Jennifer, Emmert-Tangredi, Kaitlin, Martin, Narda J., Sanghani, Shreya, Tilburt, Jon C. , Davis, Aretha Delight , Garde, Cynthia, El‐Jawahri, Areej , Quintiliani, Lisa M. , Sciacca, Kate, Tulsky, James A. , Lakin, Joshua R. , Zupanc, Sophia N. , Pollak, Kathryn I. , Barry, Michael J. , Goldman, Julie

Mayo Clinic

JAMA Network Open | May 9, 2025 | Volume: 8 | Issue: 5 | Pages: e259150

10.1001/jamanetworkopen.2025.9150 | PMID 40343696 Get It

Importance Many older adults with advanced cancer never communicate goals of care or treatment preferences to their clinicians, raising the risk that care received will not match their values. Scalable models of care may help surmount this barrier. Objective To test whether a combined patient and clinician intervention increased the rate of advance care planning (ACP) documentation in large health care systems. Design, Setting, and Participants This stepped-wedge cluster randomized clinical trial using an open cohort design included patients aged 65 years or older with advanced cancer seen at oncology clinics in 3 health care systems located in the US South, Midwest, and Mid-Atlantic regions from April 1, 2020, to November 30, 2022. Data collection ended in 2024. Intervention The intervention involved delivering brief evidence-based patient-facing video decision aids available in 25 languages as well as goals-of-care communication training to oncology clinicians. Patients in the control period received usual care. Main Outcomes and Measures The primary outcome was ACP documentation, which included any electronic health record documentation of a goals-of-care conversation, palliative care, hospice, or limitation of life-sustaining treatments, identified via a validated natural language processing program. Analysis was performed on an intention-to-treat basis. Results Twenty-nine practices, comprising 13 800 unique eligible patients with a total of 29 357 repeated measurements, were included (mean [SD] age, 74.5 [6.6] years; 52.3% men [15 344 of 29 357 measurements]). The proportion of patients with ACP documentation was greater in the intervention phase compared with the usual care phase (adjusted rate difference, 6.8% [95% CI, 2.8%-10.8%]; P < .001). ACP documentation in the intervention phase occurred among 3980 of 15 754 patients (25.3%) (goals-of-care conversation, 21.4% [3377 of 15 754]; palliative care, 9.6% [1517 of 15 754]; hospice, 5.4% [847 of 15 754]; and limitation of life-sustaining treatments, 7.2% [1128 of 15 754]). In comparison, ACP documentation in the usual care phase occurred among 2834 of 13 603 patients (20.8%) (goals-of-care conversation, 16.8% [2281 of 13 603]; palliative care, 9.5% [1287 of 13 603]; hospice, 5.3% [724 of 13 603]; and limitation of life-sustaining treatments, 8.4% [1149 of 13 603]). Conclusions and Relevance In this stepped-wedge cluster randomized clinical trial for older adults with advanced cancer, a bundled evidence-based decision aid and communication training intervention increased the proportion of older patients with ACP documentation. This approach offers an innovative paradigm with a clinically meaningful increase in ACP documentation, a widely used quality metric that reflects high-quality patient-centered care delivery. Trial Registration ClinicalTrials.gov Identifier: NCT03609177
Development of a Pentacistronic Ebola Virus Minigenome System
Zell, Brady N. , Swenson, Vaille A. , Wang, Lin , Barry, Michael A. , Yamaoka, Satoko , Lu, Shao‐Chia , Barry, Michael A , Zell, Brady , Ebihara, Hideki

Mayo Clinic

Viruses | May 9, 2025 | Volume: 17 | Issue: 5 | Pages: 688

10.3390/v17050688 | PMID 40431699 Get It

Ebola virus (EBOV) causes severe disease outbreaks in humans with high case fatality rates. EBOV requires adaptation to cause lethal disease in mice by acquiring single mutations in both the nucleoprotein (NP) and VP24 genes. As an attempt to model mouse-adapted EBOV (MA-EBOV), we engineered novel pentacistronic minigenomes (5xMG) containing a reporter gene, VP40, and glycoprotein genes as well as the NP and VP24 genes from either EBOV or MA-EBOV. The 5xMGs were constructed and optimized, and the produced transcription- and replication-competent virus-like particles (trVLPs) were demonstrated to infect several cell lines. Introduction of the mouse-adaptation mutations did not significantly impact the replication and transcription of the 5xMG or the relative infectivity of the trVLPs in vitro. This work demonstrates the development of the 5xMG system as a new versatile tool to study EBOV biology.
Clinical Outcomes of Mitral Regurgitation Severity and Transcatheter Edge‐to‐Edge Repair in Atrial Functional Mitral Regurgitation
Naser, Jwan A. , Massad, Faysal, Borlaug, Barry A. , Simard, Trevor , Siontis, Konstantinos C. , Kennedy, Austin M , Thaden, Jeremy J. , Eleid, Mackram F. , Borlaug, Barry A , Simard, Trevor , Eleid, Mackram F , Naser, Jwan A , Scott, Christopher G. , Michelena, Héctor I. , Pellikka, Patricia A. , Nkomo, Vuyisile T. , Pislaru, Sorin V.

Mayo Clinic

Catheterization and Cardiovascular Interventions | May 5, 2025 | Volume: 106 | Issue: 1 | Pages: 494-503

10.1002/ccd.31567 | PMID 40320723 Get It

ABSTRACT Background Incident atrial functional mitral regurgitation (AFMR) is associated with mortality. Transcatheter edge‐to‐edge repair (TEER) has shown effectiveness in improving MR and symptoms in AFMR, but previous studies lacked comparison to conservative management. We aimed to study the association of AFMR severity and mitral TEER with symptoms, heart failure hospitalizations (HFH) and all‐cause mortality in moderate/severe AFMR. Methods Consecutive adults with moderate/severe AFMR managed conservatively or with TEER 2010−2023 were identified retrospectively. To ensure similar technique in evaluation in the two groups, variables were obtained from the closest transthoracic echocardiogram before TEER in the TEER group. In addition to multivariable analysis, the association of TEER (vs. conservative management) with HFH and mortality was assessed using propensity‐score matched analyses; the propensity score was based on age, sex, EuroSCORE II, effective regurgitant orifice area, integrative MR severity, and NYHA class III/IV (vs. I/II). Results Among 230 patients with moderate/severe AFMR [mean age 77; 56% females], 46 were managed with TEER. Severe (vs. moderate) AFMR was independently associated with baseline NYHA class III/IV (multivariable OR 2.18 [95% CI 1.13−4.26]) and HFH [multivariable HR 2.75 (95% CI 1.25−6.03)] but not mortality ( p = 0.26). TEER improved MR to ≤ moderate in 93% but was not associated with lower HFH or death rates versus conservative management on multivariable or matched analysis. However, 1‐year NYHA improved more with TEER versus conservative management in patients with baseline NYHA class III/IV (62% vs. 27%, p = 0.03). Rhythm control was associated with improved survival (HR 0.38 [0.15−0.98]). Conclusions AFMR severity was associated with symptoms and HFH but not mortality. MR severity and NYHA class improved with TEER, but the association of TEER with HF hospitalizations or death remains unproven. Randomized studies are needed to evaluate the potential role of TEER and rhythm control on outcomes in AFMR.
Machine Learning Prediction of Left Ventricular Assist Device Thrombosis from Acoustic Harmonic Power
Carlson, Kent, Dragomir‐Daescu, Dan , Boilson, Barry A. , Carlson, Kent D, Razonable, Raymund R

Mayo Clinic

Bioengineering | May 2, 2025 | Volume: 12 | Issue: 5 | Pages: 484

10.3390/bioengineering12050484 | PMID 40428103 Get It

Left ventricular assist device (LVAD) thrombosis typically presents late and may have devastating consequences for patients. While LVAD pump thrombosis is uncommon with current pump designs, many patients worldwide remain supported with previous generations of LVADs, including the HeartWare device (HVAD). Researchers have focused on investigating the acoustic signatures of LVADs to enable earlier detection and treatment of this condition. This study explored the use of machine learning algorithms to predict thrombosis from harmonic power values determined from the acoustic signatures of a cohort of HVAD patients (n = 11). The current dataset was too small to develop a predictive model for new data, but exhaustive cross validation indicated that machine learning models using the first two or the first three harmonic power values both resulted in reasonable prediction accuracy of the thrombosis outcome. Furthermore, when principal component analysis (PCA) was applied to the harmonic power variables from these promising models, the use of the resulting PCA variables in machine learning models further increased the thrombosis outcome prediction accuracy. K-nearest neighbor (KNN) models gave the best predictive accuracy for this dataset. Future work with a larger HVAD recording dataset is necessary to develop a truly predictive model of HVAD thrombosis. Such a predictive model would provide clinicians with a marker to detect HVAD thrombosis based directly on pump performance, to be used along with current clinical markers.
SGLT2 inhibitors and cardiovascular outcomes in patients with acute myocardial infarction: a retrospective cohort analysis
Mee, Xuan Ci , Lim, Ghee Kheng, Ibrahim, Ramzi , Abdelnabi, Mahmoud , Allam, Mohamed , Bcharah, George , Barry, Timothy, Ayoub, Chadi , Arsanjani, Reza, Ci Mee, Xuan, Kheng Lim, Ghee, Allam, Mohamed N , Tan, Min Choon , Ayoub, Chadi , Ibrahim, Ramzi , Lim, Ghee Kheng, Pham, Hoang Nhat , Farina, Juan M. , Arsanjani, Reza , Lee, Kwan

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | April 26, 2025 | Volume: 11 | Issue: 4 | Pages: 334-342

10.1093/ehjcvp/pvaf026 | PMID 40285691 Get It

Abstract Aims Sodium-glucose cotransporter 2 inhibitors (SGLT2-Is) improve heart failure (HF) outcomes but their effects on acute myocardial infarction (AMI) remain poorly characterized. This study aimed to evaluate the 1-year cardiovascular outcomes of SGLT2-Is among patients with AMI. Methods and results We conducted an observational, retrospective cohort study using TriNetX data, including patients aged ≥18 with AMI identified via ICD-10 codes regardless of left ventricular ejection fraction (LVEF), categorized by SGLT2-Is use. Propensity score matching (PSM) was performed to balance baseline demographics, comorbidities, and medication use. Adjusted odds ratios (aORs) were estimated for the primary outcome (recurrent AMI) and the secondary outcomes (acute HF hospitalizations, stroke, all-cause hospitalizations, all-cause mortality, new-onset atrial fibrillation, and cardiac arrest). After PSM, 89 554 patients were analysed (44 777 SGLT2-Is users; 44 777 non-users). The mean age was ∼68 years in both cohorts with a similarly high burden of cardiovascular comorbidities. Mean follow-up duration was 290.854 days for SGLT2-Is users and 284.465 days for non-users. SGLT2-Is use was linked to lower rates of recurrent AMI [aOR: 0.459; 95% confidence interval (CI): 0.367–0.551], all-cause hospitalizations (aOR: 0.782; 95% CI: 0.762–0.803), all-cause mortality (aOR: 0.640; 95% CI: 0.612–0.670), and cardiac arrest (aOR: 0.834; 95% CI: 0.773–0.900). No differences were observed in acute HF hospitalizations, new-onset atrial fibrillation, or stroke. Conclusion SGLT2-Is are associated with improved cardiovascular outcomes in patients with AMI, including reductions in recurrent AMI, all-cause hospitalizations and mortality, and cardiac arrest. These findings emphasize the need for prospective clinical trials involving patients with AMI and other cardiovascular comorbidities, regardless of LVEF, to confirm these results.